GLP-1 medications: use and interest in a representative survey of Finns
Authors' conclusion
GLP-1-based medications are gaining recognition, but uptake remains heterogeneous and many individuals with obesity remain uninterested. Concerns about potential health risks persist. Attitudes toward these medications are shaped not only by weight status but also by prior weight management experiences and perceptions.
Study context
- Population
- Finnish adults, nationally representative online survey, June 20251,693 included
- Participants
- 1,729 adults
- Outcome
- Use of and interest in GLP-1 medications for obesity
Methodological detailsnationally representative online survey, quota sampling
- Nationally representative online survey
- Quota sampling
Main finding
As reported in the abstract
Current use
3.5%
Past use
2.0%
Interest in future use
13.5%
Individuals with obesity reporting no interest
≈40%
Observational data: associations, not effects.
Further findings
Correlates of current use (bivariate analysis)
- Current use more common among women, those aged 50-69, household income >€70,000, higher BMI, frequent weight loss attempts, weight-based discrimination and self-blame
Correlates of current, past and potential use (multivariable analysis; n = 322 users combined)
- Strongest associations with BMI ≥30.0 kg/m², repeated or persistent weight loss attempts, discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications
- Concern about serious health risks associated with lower likelihood of use or interest
Original publication
GLP-1 medications: use and interest in a representative survey of Finns. Int J Obes (Lond). Published 7 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →